New study is the first to characterize pegloticase use in the dialysis population.
Researchers evaluated the onset of comorbidities and flare patterns, based on baseline comorbidity clusters in patients with gout.
Researchers evaluated the effect of mycophenolate mofetil on the efficacy of pegloticase in patients with refractory gout.
Researchers studied metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and discovered potential metabolite biomarkers to differentiate between gout and asymptomatic hyperuricemia.
Researchers tested the hypothesis that the association of traits representing hyperuricemia and its comorbidities is genetically based.
Robert T. Keenan, MD, discusses the role of co-treatment with immunomodulators and pegloticase in patients with uncontrolled gout.
Rates of in-hospital cardiac procedures continued to increase in people with gout and rheumatoid arthritis (RA) from 1998 to 2014.
Researchers assessed the incidence and potential risk factors for the development offenofibrate-associated nephrotoxicity in patients with gout.
Researchers investigated the association between weight change patterns during adulthood and incident gout.
Researchers assessed the effect of hyperuricemia, induced by inosine supplementation, on bone turnover markers in postmenopausal women during a 6-month period.